In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin

Ann Intern Med. 2023 Jan;176(1):JC8. doi: 10.7326/J22-0104. Epub 2023 Jan 3.

Abstract

GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, et al. Glycemia reduction in type 2 diabetes-glycemic outcomes. N Engl J Med. 2022;387:1063-74. 36129996.

Publication types

  • Comment

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 2* / drug therapy
  • Drug Therapy, Combination
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin Glargine / therapeutic use
  • Liraglutide / therapeutic use
  • Metformin* / therapeutic use
  • Sitagliptin Phosphate / therapeutic use
  • Treatment Outcome

Substances

  • Insulin Glargine
  • glimepiride
  • Sitagliptin Phosphate
  • Liraglutide
  • Hypoglycemic Agents
  • Blood Glucose
  • Metformin